2-(6-ethyl-2-methyl-1-(4-(methylsulfonyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid

ID: ALA4086277

PubChem CID: 137643575

Max Phase: Preclinical

Molecular Formula: C20H22N2O4S

Molecular Weight: 386.47

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CCc1ccc2c(CC(=O)O)c(C)n(Cc3ccc(S(C)(=O)=O)cc3)c2n1

Standard InChI:  InChI=1S/C20H22N2O4S/c1-4-15-7-10-17-18(11-19(23)24)13(2)22(20(17)21-15)12-14-5-8-16(9-6-14)27(3,25)26/h5-10H,4,11-12H2,1-3H3,(H,23,24)

Standard InChI Key:  QKTZDUXKWPIHAY-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 27 29  0  0  0  0  0  0  0  0999 V2000
   24.2887   -7.1112    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   23.8843   -6.4055    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   23.4753   -7.1086    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   21.0540   -3.9629    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.7150   -3.4822    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.4598   -2.7032    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4925   -3.7336    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.9373   -2.0400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.7504   -2.1219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.2279   -1.4587    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   23.0860   -2.8670    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   21.0553   -4.7801    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.7637   -5.1876    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.7614   -6.0021    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4690   -6.4094    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1770   -5.9996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1730   -5.1782    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4649   -4.7746    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.5924   -5.9954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.3915   -3.4844    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.6443   -2.7114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.1018   -2.1080    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.3063   -2.2764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.0563   -3.0536    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.6005   -3.6537    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.2575   -3.2261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.7087   -2.6206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
 20  4  1  0
  4  5  1  0
  5  6  2  0
  6 21  1  0
  5  7  1  0
  6  8  1  0
  8  9  1  0
  9 10  2  0
  9 11  1  0
  4 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 13  1  0
 16  2  1  0
  2 19  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 20  1  0
 24 26  1  0
 26 27  1  0
M  END

Alternative Forms

  1. Parent:

    ALA4086277

    ---

Associated Targets(Human)

PTGDR2 Tchem G protein-coupled receptor 44 (4688 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 386.47Molecular Weight (Monoisotopic): 386.1300AlogP: 2.99#Rotatable Bonds: 6
Polar Surface Area: 89.26Molecular Species: ACIDHBA: 5HBD: 1
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 4.46CX Basic pKa: 3.80CX LogP: 2.19CX LogD: -0.32
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.70Np Likeness Score: -1.20

References

1. Sandham DA, Barker L, Brown L, Brown Z, Budd D, Charlton SJ, Chatterjee D, Cox B, Dubois G, Duggan N, Hall E, Hatto J, Maas J, Manini J, Profit R, Riddy D, Ritchie C, Sohal B, Shaw D, Stringer R, Sykes DA, Thomas M, Turner KL, Watson SJ, West R, Willard E, Williams G, Willis J..  (2017)  Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.,  (5): [PMID:28523115] [10.1021/acsmedchemlett.7b00157]

Source